Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma

Figure 4 Diagnostic value of protein induced by vitamin K absence or antagonist II, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase to aspartate aminotransferase in hepatitis B virus DNA+ hepatocellular carcinoma patients. A-C: Comparisons of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), and the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST) between hepatitis B virus (HBV) DNA+ hepatocellular carcinoma (HCC) patients and HBV DNA+ chronic hepatitis B (CHB) patients; D: Receiver-operating characteristic (ROC) curves of PIVKA-II, AFP, and γ-GT/AST in HBV DNA+ HCC patients; HBV DNA+ CHB patients served as controls; E: ROC curves of the combinations of PIVKA-II, AFP, and γ-GT/AST in HBV DNA+ HCC patients; HBV DNA+ CHB patients served as controls. PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B; ROC curve: Receiver-operating characteristic curve.